The current prostate cancer disease burden is considerable due to the high prevalence of the disease, widespread early detection, and the relatively long survival time since many men will die with rather than due to prostate cancer. In the United States, one in every three new cases of cancer in men is prostate cancer. Worldwide, in 2002, it was predicted that 679,023 men received the diagnosis…
The Martini Clinic, a private clinic located at the Hamburg-Eppendorf University Hospital (UKE), specialises exclusively in the diagnosis and therapy of one medical condition: prostate cancer.
Urology is a surgical speciality with a limited number of consultants in Europe (around 134,000). The field is very well organised and active.
AstraZeneca has been collaborating with researchers who detected a potential Aurora B inhibitor.
USA - Engineers are developing a tiny wireless device - the size of a rice grain - to be implanted in tumours to indicate the precise radiation dose received and to locate the exact position of tumours during treatment.
Lithoskop, a new multifunctional lithotripsy system, is to be publicly launched by Siemens Medical Solutions at the European Association of Urology Congress, to be held in Istanbul, Turkey this March.
Denmark - Regular drinkers significantly increase their risk of rectal cancer, but that risk is reduced if wine makes up a third or more of weekly consumption, according to research carried out by Professor Morten Grønbaek, at the Centre for Alcohol Research, National Institute of Public Health, Copenhagen, published in the journal GUT.
Dry Cut, a new cutting mode produced specifically for transurethral resection of the prostate (TUR-P), has been launched by Erbe Elektromedizin, of Tubingen, Germany. This, with High Cut and Auto Cut, means that Erbes VIO System now offers the entire range of cutting qualities needed for TUR-P, TUR-B and TUV-P procedures, the firm reports.
An interview with Dr Andre Roggan, head of research and development at Celon AG, and Dr Markus Mueller, consultant at the Urology Clinic at the University Clinic Benjamin Franklin, Free University Berlin. Venue: 1st International Workshop on Radio-frequency Induced Thermotherapy (RFITT) for the treatment of BPH
Prostate cancer, the most common neoplasm in men, often progresses from an androgen-dependant state (and is commonly treated by androgen ablation therapies) to a hormone-refractory stage, therefore making hormone therapy ineffective. The response duration to androgen ablation therapy is finite and ultimately most prostate cancer will become hormone-insensitive.
Prostate cancer (PCa) is not only one of the most common, but also one of the deadliest types of cancer in men. Diagnostics are correspondingly sophisticated, from imaging via ultrasound or MRI to various biopsy techniques – often even in combination. Keep reading for current developments in early detection, staging, therapy and research.
